FiercePharmaOriginal article
{"a":[{"_":"AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market","$":{"href":"/pharma/abbvies-skyrizi-reaches-new-heights-it-continues-thrive-growing-psoriasis-market","hreflang":"en"}}]}
EarningsSkyriziHumiraPositive
AI Analysis
Summary
AbbVie's Skyrizi generated $5.55 billion in Q2 sales, matching Humira's single-quarter peak, demonstrating strong market performance as an IL-23 inhibitor in the growing psoriasis market.
Financial Highlights
Revenue
$5.55 billion
Importance:5/10
Sentiment:
0.80
earningscommercial performancepsoriasisIL-23 inhibitorrevenue growth
Related Companies
Read the original article
Published by FiercePharma on July 31, 2026 10:45 AM
